Phases of trials

Phases of trials

Clinical trials are commonly conducted in phases, each with a distinct purpose, scope, and methodology. Understanding these phases helps clarify where a trial fits within the larger research pipeline, from early safety assessments to widespread implementation.

Phase 0: Exploratory (Microdosing) Trials

Also known as “first-in-human” studies. Phase 0 trials are optional early-phase studies involving very small doses of a drug (sub-therapeutic) given to a small number of participants, usually fewer than 15.

Purpose:

• Assess pharmacokinetics (PK) and pharmacodynamics (PD)
• Inform go/no-go decisions before Phase I

Key Features:

• Non-therapeutic
• No clinical benefit expected
• Helps identify promising candidates for further testing

Phase I: Safety and Dose-Finding

Phase I trials are the first stage of testing in humans, usually involving 20–100 healthy volunteers or patients (for high-risk drugs like cancer treatments).

Purpose:

• Assess safety and tolerability
• Determine safe dosage range
• Identify side effects

Design Elements:

• Open-label or dose-escalation design (e.g., 3+3 or Bayesian adaptive models)
• Focus on maximum tolerated dose (MTD)

Phase II: Efficacy and Side Effects

Phase II trials further evaluate the efficacy of an intervention and continue to assess its safety, typically in 100–300 participants with the target condition.

Purpose:

• Preliminary evidence of clinical effect
• Continued safety assessment
• Optimal dosing

Design Elements:

• Often randomized and controlled
• May use surrogate outcomes
• Can be split into Phase IIa (dose exploration) and Phase IIb (efficacy confirmation)

Phase III: Confirmatory Efficacy Trials

Phase III trials are large-scale RCTs involving hundreds to thousands of participants across multiple sites. These trials provide the definitive evidence needed for regulatory approval.

Purpose:

• Confirm therapeutic benefit
• Compare to standard of care
• Identify less common side effects
• Establish risk-benefit profile

Design Elements:

• Often multicenter, randomized, double-blind
• Pre-specified primary hypothesis
• May include interim analyses and data safety monitoring boards (DSMBs)

Phase IV: Post-Marketing Surveillance

Phase IV trials are conducted after regulatory approval to monitor the long-term effectiveness and safety of a treatment in real-world settings.

Purpose:

• Detect rare or long-term adverse effects
• Study effectiveness in diverse populations
• Assess cost-effectiveness and quality of life

Design Elements:

• Observational or pragmatic RCTs
• May be mandated by regulators
• Often use registry data or health records

Summary Table

Phase	Primary Goal	Participants	Design Focus
Phase 0	PK/PD, feasibility	<15	Microdosing, no therapeutic intent
Phase I	Safety, dose range	20–100	Dose-escalation, tolerability
Phase II	Preliminary efficacy	100–300	Controlled, surrogate outcomes
Phase III	Confirm efficacy, safety	300–3000+	Hypothesis-driven, regulatory-focused
Phase IV	Long-term effects, safety	Thousands	Real-world, post-approval

Integration with Trial Design

The phase of a trial often influences the:

• Type of hypothesis tested (Hypothesis)
• Level of monitoring and oversight
• Statistical methods used
• Ethical considerations (e.g., acceptable risk-benefit ratio)

Conclusion

Understanding the phases of clinical trials is essential for designing, conducting, and interpreting research appropriately. Each phase serves a distinct purpose in the journey from bench to bedside, ensuring that interventions are safe, effective, and beneficial to patients.

---

Bibliography

1. U.S. Food and Drug Administration (FDA). The Drug Development Process: Step 3 – Clinical Research. Available from: https://www.fda.gov
2. Chow S-C, Liu JP. Design and Analysis of Clinical Trials: Concepts and Methodologies. 3rd ed. Wiley; 2013. Chapter 2: Clinical trial phases and regulatory framework.
3. van Norman GA. Drugs, devices, and the FDA: Part 1. An overview of approval processes for drugs. JACC: Basic to Translational Science. 2016;1(3):170–179.
4. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery. 2008;7(1):13–14. Discusses operational characteristics of different trial phases.
5. ICH Harmonised Guideline. General Considerations for Clinical Studies E8(R1). International Council for Harmonisation; 2019. Describes objectives and design considerations by phase.

---

Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.